CH Biotech Ser (08037) Announces Potential Net Loss Reduction for FY2025

Bulletin Express03-06

China Biotech Services Holdings Limited, operating under the name CH Biotech Ser (08037), has released a profit warning indicating that its net loss for the year ended 31 December 2025 (FY2025) is expected to be not more than HK$100.00 million. This figure represents a drop of around 60% from the HK$252.00 million loss recorded for the year ended 31 December 2024 (FY2024).

The company attributes the improvement primarily to an insurance claim of approximately HK$14.00 million linked to construction damage from a rainstorm in FY2024, lower research and development costs in its immunotherapy segment, reduced administrative expenses through cost control measures, and the absence of one-off impairment losses reported in FY2024. The figures are based on preliminary unaudited management accounts and may be subject to change upon finalization of the audited results, scheduled for release by the end of March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The information provided is preliminary, and the audited consolidated annual results to be announced will contain full details regarding the company’s financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120460185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120460185","market":"us","top_or_hot":-1,"title":"CH Biotech Ser (08037) Announces Potential Net Loss Reduction for FY2025","media":"Bulletin Express","content":"<p>China Biotech Services Holdings Limited, operating under the name CH Biotech Ser (08037), has released a profit warning indicating that its net loss for the year ended 31 December 2025 (FY2025) is expected to be not more than HK$100.00 million. This figure represents a drop of around 60% from the HK$252.00 million loss recorded for the year ended 31 December 2024 (FY2024).</p>\n<p>The company attributes the improvement primarily to an insurance claim of approximately HK$14.00 million linked to construction damage from a rainstorm in FY2024, lower research and development costs in its immunotherapy segment, reduced administrative expenses through cost control measures, and the absence of one-off impairment losses reported in FY2024. The figures are based on preliminary unaudited management accounts and may be subject to change upon finalization of the audited results, scheduled for release by the end of March 2026.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The information provided is preliminary, and the audited consolidated annual results to be announced will contain full details regarding the company’s financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CH Biotech Ser (08037) Announces Potential Net Loss Reduction for FY2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCH Biotech Ser (08037) Announces Potential Net Loss Reduction for FY2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-06 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Biotech Services Holdings Limited, operating under the name CH Biotech Ser (08037), has released a profit warning indicating that its net loss for the year ended 31 December 2025 (FY2025) is expected to be not more than HK$100.00 million. This figure represents a drop of around 60% from the HK$252.00 million loss recorded for the year ended 31 December 2024 (FY2024).</p>\n<p>The company attributes the improvement primarily to an insurance claim of approximately HK$14.00 million linked to construction damage from a rainstorm in FY2024, lower research and development costs in its immunotherapy segment, reduced administrative expenses through cost control measures, and the absence of one-off impairment losses reported in FY2024. The figures are based on preliminary unaudited management accounts and may be subject to change upon finalization of the audited results, scheduled for release by the end of March 2026.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The information provided is preliminary, and the audited consolidated annual results to be announced will contain full details regarding the company’s financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08037","symbol_name":"中国生物科技服务","start_time":0,"source_url":"","article_id":"1120460185","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120460185","pubTimestamp":1772802167,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Biotech Services Holdings Limited, operating under the name CH Biotech Ser (08037), has released a profit warning indicating that its net loss for the year ended 31 December 2025 (FY2025) is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08037":"中国生物科技服务"},"translate_title":"CH Biotech Ser(08037)宣布2025财年净亏损可能减少","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08037":1},"content_text":"China Biotech Services Holdings Limited, operating under the name CH Biotech Ser (08037), has released a profit warning indicating that its net loss for the year ended 31 December 2025 (FY2025) is expected to be not more than HK$100.00 million. This figure represents a drop of around 60% from the HK$252.00 million loss recorded for the year ended 31 December 2024 (FY2024).\nThe company attributes the improvement primarily to an insurance claim of approximately HK$14.00 million linked to construction damage from a rainstorm in FY2024, lower research and development costs in its immunotherapy segment, reduced administrative expenses through cost control measures, and the absence of one-off impairment losses reported in FY2024. The figures are based on preliminary unaudited management accounts and may be subject to change upon finalization of the audited results, scheduled for release by the end of March 2026.\nShareholders and potential investors are advised to exercise caution when dealing in the company’s shares. The information provided is preliminary, and the audited consolidated annual results to be announced will contain full details regarding the company’s financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120460185","isCrawlerRequest":true}